Published in Blood on June 01, 2002
Tissue factor and thrombosis: The clot starts here. Thromb Haemost (2010) 1.16
Up-regulation of tissue factor in human pulmonary artery endothelial cells after ultrafine particle exposure. Environ Health Perspect (2007) 1.03
Analysis of tissue factor positive microparticles. Thromb Res (2010) 0.95
Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. Lupus (2010) 0.86
"Soluble Tissue Factor" in the 21st Century: Definitions, Biochemistry, and Pathophysiological Role in Thrombus Formation. Semin Thromb Hemost (2015) 0.75
Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med (2003) 2.93
CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol (2002) 1.92
Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation (2009) 1.84
MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med (2006) 1.79
EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury. Am J Pathol (2005) 1.62
Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation (2004) 1.57
A mechanistic analysis of the role of microcalcifications in atherosclerotic plaque stability: potential implications for plaque rupture. Am J Physiol Heart Circ Physiol (2012) 1.55
Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation (2003) 1.42
Platelet deposition inhibits tissue factor activity: in vitro clots are impermeable to factor Xa. Blood (2004) 1.38
In vivo noninvasive detection and age definition of arterial thrombus by MRI. J Am Coll Cardiol (2002) 1.33
Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis (2003) 1.31
Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation (2005) 1.31
High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol (2004) 1.30
Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm (2010) 1.28
Serial studies of mouse atherosclerosis by in vivo magnetic resonance imaging detect lesion regression after correction of dyslipidemia. Arterioscler Thromb Vasc Biol (2004) 1.27
2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol (2011) 1.24
Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood (2002) 1.21
Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis (2002) 1.21
Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis. Circulation (2004) 1.09
Progression and regression of atherosclerotic lesions: monitoring with serial noninvasive magnetic resonance imaging. Circulation (2002) 1.09
Intravascular epithelioid hemangioendothelioma of the inferior vena cava: case report of an unusual and unpredictable vascular tumor. Cardiovasc Pathol (2008) 1.09
The synergism of age and db/db genotype impairs wound healing. Exp Gerontol (2007) 1.07
The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. J Am Coll Cardiol (2004) 1.05
Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. J Am Coll Cardiol (2008) 1.03
Quantification of human atherosclerotic plaques using spatially enhanced cluster analysis of multicontrast-weighted magnetic resonance images. Magn Reson Med (2004) 1.01
Alterations in myocardial tissue factor expression and cellular localization in dilated cardiomyopathy. J Am Coll Cardiol (2005) 0.98
Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. Atherosclerosis (2005) 0.98
Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study). J Heart Lung Transplant (2004) 0.96
Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit. Eur J Med Chem (2009) 0.94
Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion. Blood (2003) 0.94
MCP-1 deficiency is associated with reduced intimal hyperplasia after arterial injury. Biochem Biophys Res Commun (2003) 0.93
Prediction of heart transplant rejection with a breath test for markers of oxidative stress. Am J Cardiol (2004) 0.92
Hydrogel-embedded endothelial progenitor cells evade LPS and mitigate endotoxemia. Am J Physiol Renal Physiol (2011) 0.91
A novel nonobstructive intravascular MRI coil: in vivo imaging of experimental atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 0.90
Subphysiologic apolipoprotein E (ApoE) plasma levels inhibit neointimal formation after arterial injury in ApoE-deficient mice. Arterioscler Thromb Vasc Biol (2004) 0.90
Decreased reendothelialization and increased neointima formation with endostatin overexpression in a mouse model of arterial injury. Circulation (2003) 0.88
High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol (2014) 0.87
Remodeling of small intramyocardial coronary arteries distal to a severe epicardial coronary artery stenosis. Arterioscler Thromb Vasc Biol (2002) 0.87
Vascular endothelial growth factor-C induces lymphangitic carcinomatosis, an extremely aggressive form of lung metastases. Cancer Res (2010) 0.86
Hepatocyte growth factor is a survival factor for endothelial cells and is expressed in human atherosclerotic plaques. Atherosclerosis (2002) 0.86
Effects of simvastatin on plasma lipoproteins and response to arterial injury in wild-type and apolipoprotein-E-deficient mice. J Vasc Res (2004) 0.86
Serial, noninvasive, in vivo magnetic resonance microscopy detects the development of atherosclerosis in apolipoprotein E-deficient mice and its progression by arterial wall remodeling. J Magn Reson Imaging (2003) 0.86
Primary pulmonary artery leiomyosarcoma. Cardiovasc Pathol (2003) 0.85
Phospholipid regulates the activation of factor X by tissue factor/factor VIIa (TF/VIIa) via substrate and product interactions. Biochemistry (2005) 0.84
Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates. J Am Coll Cardiol (2002) 0.83
TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. Am J Surg Pathol (2016) 0.83
The p17 cleaved form of caspase-3 is present within viable macrophages in vitro and in atherosclerotic plaque. Arterioscler Thromb Vasc Biol (2003) 0.83
Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. Atherosclerosis (2006) 0.83
Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity. Bioorg Med Chem (2006) 0.82
Lipid-bound factor Xa regulates tissue factor activity. Biochemistry (2007) 0.81
Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice. Biochem Biophys Res Commun (2005) 0.81
Giant myxoma causing heart failure symptoms. Am J Case Rep (2012) 0.80
Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide] as a clinical candidate. Bioorg Med Chem Lett (2010) 0.80
Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis. Pathophysiol Haemost Thromb (2008) 0.79
Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol. Transplantation (2002) 0.79
New experimental setup for studying strictly noninvasively skeletal muscle function in rat using 1H-magnetic resonance (MR) imaging and 31P-MR spectroscopy. Magn Reson Med (2005) 0.79
Atherosclerotic lesions in genetically modified mice quantified in vivo by non-invasive high-resolution magnetic resonance microscopy. Atherosclerosis (2002) 0.79
Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett (2005) 0.78
Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation. Am J Surg Pathol (2015) 0.78
Circulating monocytes mirror the imbalance in TF and TFPI expression in carotid atherosclerotic plaques with lipid-rich and calcified morphology. Thromb Res (2011) 0.78
AECVP and SCVP 2009 recommendations for training in cardiovascular pathology. Cardiovasc Pathol (2010) 0.77
Thrombin binding to GPIbalpha induces integrin alphaIIbbeta3 dependent platelet adhesion to fibrin in ex vivo flowing whole blood. Thromb Haemost (2004) 0.77
Local shear conditions and platelet aggregates regulate the incorporation and activity of circulating tissue factor in ex-vivo thrombi. Thromb Haemost (2002) 0.77
Benign and Malignant Brenner Tumors Show an Absence of TERT Promoter Mutations That Are Commonly Present in Urothelial Carcinoma. Am J Surg Pathol (2016) 0.76
Synthesis and structure-activity studies of novel orally active non-terpenoic 2,3-oxidosqualene cyclase inhibitors. J Med Chem (2003) 0.76
Automated classification of atherosclerotic plaque from magnetic resonance images using predictive models. Biosystems (2006) 0.76
Induction of fractalkine by endothelial cells under shear stress. Blood Coagul Fibrinolysis (2004) 0.76
Endovascular aortic biopsy in the diagnosis of takayasu arteritis. J Endovasc Ther (2003) 0.76
Enhancing the anticoagulant potency of soluble tissue factor mutants by increasing their affinity to factor VIIa. Thromb Haemost (2002) 0.76
Phospholipid surfaces regulate the delivery of substrate to tissue factor:VIIa and the removal of product. Blood Cells Mol Dis (2006) 0.76
Up against the wall. Blood (2005) 0.75
A simple experiment and a weakening paradigm: the contribution of blood to propensity for thrombus formation. Arterioscler Thromb Vasc Biol (2002) 0.75
Toward a cardiovascular pathology training report on the forum held in Vancouver, March 6, 2004, Society for Cardiovascular Pathology. Cardiovasc Pathol (2005) 0.75
Refractory pulmonary hypertension in a lupus patient with occult pulmonary vasculitis. J Clin Rheumatol (2003) 0.75
Low thrombogenicity of calcified atherosclerotic plaques is associated with bone morphogenetic protein-2-dependent inhibition of tissue factor expression. Blood Coagul Fibrinolysis (2011) 0.75
Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype. Bioorg Med Chem Lett (2012) 0.75
Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold. Bioorg Med Chem Lett (2012) 0.75
Giant cell aortitis with histopathologic and clinical response to steroid therapy: a case report. J Thorac Cardiovasc Surg (2006) 0.75